Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Portfolio Pulse from
Cybin Inc. has launched a strategic partnership with Segal Trials to support its Phase 3 program for CYB003, aimed at treating Major Depressive Disorder.
January 15, 2025 | 5:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. has initiated a strategic partnership with Segal Trials to advance its Phase 3 clinical program for CYB003, a treatment for Major Depressive Disorder.
The partnership with Segal Trials is a significant step in advancing Cybin's Phase 3 program for CYB003, which could lead to successful treatment options for Major Depressive Disorder. This development is likely to positively impact Cybin's stock as it progresses in its clinical trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100